Apimeds Pharmaceuticals Us Stock Analysis

Apimeds Stock Analysis Notes

About 82.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.13. Apimeds Pharmaceuticals had not issued any dividends in recent years. For more info on Apimeds Pharmaceuticals US please contact Erik Emerson at 848 201 5010 or go to https://www.mindwavedao.com.

Apimeds Pharmaceuticals Investment Alerts

Apimeds Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.31 M.

Apimeds Profitablity

Management Efficiency

Apimeds Pharmaceuticals has return on total asset (ROA) of (4.0938) % which means that it has lost $4.0938 on every $100 spent on assets. This is way below average. Apimeds Pharmaceuticals' management efficiency ratios could be used to measure how well Apimeds Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Apimeds Pharmaceuticals' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 1.24 in 2026, whereas Return On Tangible Assets are likely to drop (128.55) in 2026. Total Assets is likely to drop to about 11.2 K in 2026. Other Current Assets is likely to drop to 8,040 in 2026

Technical Drivers

As of the 5th of February, Apimeds Pharmaceuticals shows the Downside Deviation of 9.35, risk adjusted performance of 0.027, and Mean Deviation of 7.08. Apimeds Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apimeds Pharmaceuticals semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if Apimeds Pharmaceuticals is priced correctly, providing market reflects its regular price of 1.71 per share. Please also double-check Apimeds Pharmaceuticals US total risk alpha, which is currently at (0.51) to validate the company can sustain itself at a future point.

Apimeds Pharmaceuticals Price Movement Analysis

Apimeds Pharmaceuticals Insider Trading Activities

Apimeds Pharmaceuticals Outstanding Bonds

Apimeds Pharmaceuticals Predictive Daily Indicators

Apimeds Pharmaceuticals Forecast Models

Apimeds Pharmaceuticals' time-series forecasting models are one of many Apimeds Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Apimeds Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Apimeds Pharmaceuticals Bond Ratings

Apimeds Pharmaceuticals US financial ratings play a critical role in determining how much Apimeds Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Apimeds Pharmaceuticals' borrowing costs.

Apimeds Pharmaceuticals Total Assets Over Time

Apimeds Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Apimeds Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Apimeds Pharmaceuticals Debt Ratio

3112.0

It appears most of the Apimeds Pharmaceuticals' assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Apimeds Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Apimeds Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Apimeds Pharmaceuticals Corporate Bonds Issued

Apimeds Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Apimeds Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Apimeds shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Apimeds Pharmaceuticals. By using and applying Apimeds Stock analysis, traders can create a robust methodology for identifying Apimeds entry and exit points for their positions.

When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.